Everlife, a provider of diagnostic products and solutions to clinical and scientific laboratories, led a $27m Series A funding round in AUM Biosciences, an oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable medicines for patients, with participation from SPRIM Global Investments. AUM will use the funds for the clinical development of its portfolio with immediate initiation of two Phase II programmes for MNK and TRK inhibitors.